HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ANDERSSON, K. Articles by STADBERG, E. Search for Related Content PubMed PubMed Citation Articles by ANDERSSON, K. Articles by STADBERG, E.

Intrauterine Release of Levonorgestrel—A New Way of Adding Progestogen in Hormone Replacement Therapy

From the Department of Obstetrics and Gynecology, East Hospital, University of Göteborg, Göteborg, Sweden.

Abstract

Forty perimenopausal women with climacteric complaints were randomly allocated to one of two estrogen-progestogen regimens. One group was treated cyclically for 3-week periods with 2 mg of estradiol (E2) valerate; during the last 10 days 250 µg of levonorgestrel was added. Another group was given 2 mg of E2 valerate a day and had a 20-µg/24-hour levonorgestrel-releasing intrauterine device (IUD) inserted. The study period was 1 year. Climacteric symptoms, bleeding patterns, and endometrial histopathology were recorded during the study. Subjective symptoms were equally diminished in both groups. In the IUD group, bleeding disturbances were gradually reduced, and 15 of 18 women became amenorrheic after 12 months, compared with the group given cyclic treatment in which all women bled regularly. No endometrial proliferation was found in any woman after 12 months. Thus, intrauterine release of 20 µg of levonorgestrel per day, in combination with orally administered E2, prevented endometrial proliferation and reduced uterine bleeding. This new approach to continuous combined hormone replacement therapy may be a well-tolerated treatment alternative in perimenopausal women.

This article has been cited by other articles:

				M. Rees and S. Hope Use of unopposed systemic estrogen therapy in non-hysterectomized women: a population-based study in the UK Menopause Int, June 1, 2008; 14(2): 83 - 84. [Abstract] [Full Text] [PDF]

				A. Peloggia, C. A. Petta, L. Bahamondes, M. Oliveira-Ribeiro, J. Zhang, and L. Salamonsen Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system Hum. Reprod., May 1, 2006; 21(5): 1129 - 1134. [Abstract] [Full Text] [PDF]

				N.R.E. Hampton, M.C.P. Rees, D.G. Lowe, I. Rauramo, D. Barlow, and J. Guillebaud Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women Hum. Reprod., September 1, 2005; 20(9): 2653 - 2660. [Abstract] [Full Text] [PDF]

				T. Luukkainen Issues to debate on the Women's Health Initiative study: Failure of estrogen plus progestin therapy for prevention of breast cancer risk Hum. Reprod., August 1, 2003; 18(8): 1559 - 1561. [Abstract] [Full Text] [PDF]

				J. SYMONS, N. KEMPFERT, and L. SPEROFF Vaginal Bleeding in Postmenopausal Women Taking Low-Dose Norethindrone Acetate and Ethinyl Estradiol Combinations Obstet. Gynecol., September 1, 2000; 96(3): 366 - 372. [Abstract] [Full Text] [PDF]

				Hormone replacement therapy DTB, November 1, 1996; 34(11): 81 - 84. [Abstract] [Full Text] [PDF]